’
Tel Aviv, Israel, September 23, 2024’ Teva Pharmaceutical Industries Ltd. announced promising results from a recent analysis at the European College of Neuropsychopharmacology (ECNP) annual congress in Milan, revealing that the treatment with deutetrabenazine has shown long-term efficacy in alleviating symptoms of Tardive Dyskinesia (TD) in European patients. This finding comes from the European cohort of the RIM-TD open-label extension (OLE) study, which monitored the condition of patients over a three-year period.
Tardive Dyskinesia, a debilitating movement disorder often resulting from long-term use of antipsychotic medications, presents significant challenges for both patients and healthcare providers. The study findings indicate that deutetrabenazine resulted in sustained improvement of TD symptoms over the entire duration of the trial. Participants reported a reduction in the severity and frequency of involuntary movements, enhancing their overall quality of life.
Importantly, the analysis highlighted the favorable safety profile of deutetrabenazine. Adverse effects were minimal, indicating that the medication was well tolerated by patients throughout the study period. As TD often requires prolonged management strategies, the sustained efficacy coupled with a positive safety profile positions deutetrabenazine as an essential therapeutic option for patients grappling with this movement disorder.
These results underscore the importance of long-term treatment strategies for managing Tardive Dyskinesia, said Dr. Insert Name, lead investigator of the study. Deutetrabenazine has the potential to significantly improve the lives of patients suffering from TD, and ongoing research is crucial to fully understand its long-term effects.
The presentation of these findings at the ECNP congress highlights the growing interest and research efforts aimed at addressing the complexities of Tardive Dyskinesia. As the medical community continues to seek effective treatments for this challenging condition, Teva’s data may contribute to a deeper understanding and broader acceptance of deutetrabenazine in clinical practice.
For further inquiries about the study or Teva’s efforts in neuropharmacology, please contact Teva Pharmaceutical Industries Ltd. or visit their website.
References:’
Insert reference information related to the study analysis
Comments